Here are the 10-Q quarterly reports from Estrella Immunopharma, Inc. (ESLA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ESLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESLA filings page.
Estrella Immunopharma, Inc. is a clinical-stage biotech focused on T‑cell therapies EB103 and EB104 and has not generated product revenue. For the quarter ended June 30, 2026 it reported a net loss of $2.3 million, and a $4.6 million net loss for the six‑month period.
Six‑month research and development expense was $2.8 million and general and administrative expense $1.5 million, largely driven by clinical trial services from related‑party Eureka and professional fees. A $0.3 million non‑cash loss arose from remeasurement of derivative liabilities tied to True‑Up share features.
Liquidity is constrained: cash and cash equivalents were $146,670 at June 30, 2026 versus current liabilities of $9.3 million, including about $8.3 million owed to Eureka under the STARLIGHT‑1 Statement of Work. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing.
Estrella Immunopharma, Inc. reported a net loss of about $2.3 million for the quarter ended March 31, 2026, slightly higher than the prior-year period, driven by ongoing clinical and corporate costs. Research and development expenses were roughly $1.4 million, mainly payments to Eureka for the STARLIGHT-1 trial, while general and administrative expenses were about $0.9 million, including a loss on the True-Up derivative.
The company ended the quarter with cash and cash equivalents of roughly $1.9 million and a working capital deficit near $6.8 million, after using about $6.7 million in operating cash, largely to reduce related-party accruals. Management states there is substantial doubt about Estrella’s ability to continue as a going concern without additional financing, despite raising approximately $8.0 million gross in a January 2026 registered direct offering and private placement. Estrella continues advancing its EB103 T-cell therapy, having dosed ten patients in the Phase I/II STARLIGHT-1 trial by quarter-end.